Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a pioneering biotechnology company dedicated to developing transformative gene editing therapies with the potential for curative outcomes. Leveraging its proprietary CRISPR/Cas9 technology platform, Intellia is advancing a pipeline of innovative treatments for serious and life-threatening diseases. The company's core strategy centers on both *in vivo* gene editing, where therapeutic edits are made directly within the patient's body, and *ex vivo* cell therapies, which involve modifying cells outside the body before reintroduction. Key *in vivo* programs include NTLA-2001, currently in Phase 1 clinical trials for transthyretin amyloidosis, and NTLA-2002, undergoing Phase 1/2 study for hereditary angioedema. Intellia is also actively researching engineered cell therapies aimed at treating various cancers and autoimmune disorders. The company has established strategic collaborations with leading organizations such as AvenCell Therapeutics, Kyverna Therapeutics, ONK Therapeutics, and ReCode Therapeutics to accelerate the development of allogeneic CAR-T cell therapies, engineered NK cell therapies, and novel genomic medicines for conditions like cystic fibrosis. This collaborative approach, combined with its internal research and development efforts, positions Intellia at the forefront of the rapidly evolving gene editing landscape, aiming to address significant unmet medical needs across a broad spectrum of diseases.